TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS
6.1. Overview
6.2. Lipopeptides
6.3. Oxazolidinones
6.4. Cephalosporin
6.5. Tetracycline
6.6. Folate Antagonist
6.7. Other Drug Classes
7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Oral Administration
7.3. Parenteral Administration
8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL
8.1. Overview
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market,
10.7. Key developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2023
10.8.2. Major Players R&D Expenditure. 2023
11. COMPANY PROFILES
11.1. Teva Pharmaceutical Industries ltd
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Cumberland Pharmaceuticals Inc
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. AbbVie Inc.
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Merck & Co Inc
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Pfizer Inc
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Theravance Biopharma
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Basilea Pharmaceutica
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. AmpliPhi Biosciences Corporation
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Debiopharm International S.A.
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Nabriva Therapeutics Plc
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Melinta Therapeutics Inc
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. Innovation Pharmaceuticals Inc.
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Products Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Paratek Pharmaceuticals, Inc.
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Products Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 9 US: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 10 US: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 11 US: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 12 CANADA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 13 CANADA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 14 CANADA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 10 ITALY: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 11 ITALY: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 12 ITALY: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 16 UK: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 17 UK: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 18 UK: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 28 CHINA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 29 CHINA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 30 CHINA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 31 INDIA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 32 INDIA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 33 INDIA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET
FIGURE 4 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY DRUG CLASS, 2023
FIGURE 5 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 6 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 7 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
FIGURE 15 CUMBERLAND PHARMACEUTICALS INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 CUMBERLAND PHARMACEUTICALS INC: SWOT ANALYSIS
FIGURE 17 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 ABBVIE INC.: SWOT ANALYSIS
FIGURE 19 MERCK & CO INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 MERCK & CO INC: SWOT ANALYSIS
FIGURE 21 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 PFIZER INC: SWOT ANALYSIS
FIGURE 23 THERAVANCE BIOPHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 THERAVANCE BIOPHARMA: SWOT ANALYSIS
FIGURE 25 BASILEA PHARMACEUTICA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 BASILEA PHARMACEUTICA: SWOT ANALYSIS
FIGURE 27 AMPLIPHI BIOSCIENCES CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 AMPLIPHI BIOSCIENCES CORPORATION: SWOT ANALYSIS
FIGURE 29 DEBIOPHARM INTERNATIONAL S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 DEBIOPHARM INTERNATIONAL S.A.: SWOT ANALYSIS
FIGURE 31 NABRIVA THERAPEUTICS PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 NABRIVA THERAPEUTICS PLC: SWOT ANALYSIS
FIGURE 33 MELINTA THERAPEUTICS INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 MELINTA THERAPEUTICS INC: SWOT ANALYSIS
FIGURE 35 INNOVATION PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 INNOVATION PHARMACEUTICALS INC.: SWOT ANALYSIS
FIGURE 37 PARATEK PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 PARATEK PHARMACEUTICALS, INC.: SWOT ANALYSIS
